Morgan Stanley Maintains on Abbott Laboratories
January 23, 2014 at 10:27 AM EST
In a report published Thursday, Morgan Stanley analyst David Lewis maintained Overweight on Abbott Laboratories (NYSE: ABT ), with a $45.00 price target. According to the report, guidance for 1Q and cash repatriation accounting created concerns, but the analysts remain focused on growth and profitability acceleration in 2H14. Repatriation was
